Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
111.01
+2.39 (+2.20%)
Delayed Quote
Updated: 9:51 AM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
29
30
Next >
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
February 20, 2025
From
Genesis Therapeutics, Inc. and Incyte
Via
Business Wire
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
February 18, 2025
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.
Via
Chartmill
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
February 18, 2025
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for.
Via
StockStory
Incyte to Present at Upcoming Investor Conferences
February 18, 2025
From
Incyte
Via
Business Wire
What Analysts Are Saying About Incyte Stock
↗
February 11, 2025
Via
Benzinga
Insights into Incyte Q4 Earnings
↗
February 10, 2025
Via
Benzinga
NASDAQ:INCY, an undervalued stock with good fundamentals.
↗
December 26, 2024
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
What's going on in today's pre-market session: S&P500 movers
↗
February 11, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Via
Chartmill
Why Incyte (INCY) Shares Are Plunging Today
February 10, 2025
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products such as...
Via
StockStory
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
↗
February 10, 2025
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while...
Via
Benzinga
Topics
Government
World Trade
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
↗
December 19, 2024
Via
Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
↗
February 10, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Gapping S&P500 stocks in Monday's session
↗
February 10, 2025
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Via
Chartmill
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches
↗
February 10, 2025
Incyte projects 2025 Jakafi revenue of $2.925B-$2.975B, up 4.76%-6.55%, and Opzelura sales of $630M-$670M, reflecting up to 31.81% growth.
Via
Benzinga
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
February 10, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per share...
Via
StockStory
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
February 10, 2025
From
Incyte
Via
Business Wire
Earnings Scheduled For February 10, 2025
↗
February 10, 2025
Via
Benzinga
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
February 09, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.
Via
StockStory
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Incyte
Via
Business Wire
Promising Signs: INCYTE CORP Setting the Stage for a Breakout.
↗
February 05, 2025
Exploring INCYTE CORP's Technical Signals and Breakout Potential: Based on good technical signals, INCYTE CORP is potentially setting up for a breakout.
Via
Chartmill
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
↗
January 24, 2025
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.
Via
Chartmill
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
January 21, 2025
From
Incyte
Via
Business Wire
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
↗
January 14, 2025
Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.
Via
Benzinga
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2025
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
December 17, 2024
From
Incyte
Via
Business Wire
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
December 17, 2024
Via
ACCESSWIRE
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
December 16, 2024
Via
ACCESSWIRE
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
December 13, 2024
Via
ACCESSWIRE
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
↗
December 13, 2024
Via
The Motley Fool
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
